Convalescent plasma therapy in patients with severe COVID-19, A single-arm, retrospective study
- 12 March 2022
- journal article
- research article
- Published by Elsevier BV in Microbial Pathogenesis
- Vol. 165, 105482
- https://doi.org/10.1016/j.micpath.2022.105482
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019The Journal of Infectious Diseases, 2020
- Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)Clinical Infectious Diseases, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- StatPearls2020
- Clinical trial design for orthodontistsJournal of Orthodontics, 2013
- Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potentialReviews in Medical Virology, 2011
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011